<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362170">
  <stage>Registered</stage>
  <submitdate>2/03/2012</submitdate>
  <approvaldate>16/04/2012</approvaldate>
  <actrnumber>ACTRN12612000420842</actrnumber>
  <trial_identification>
    <studytitle>Novel Treatment of Phobias in Children and Teenagers</studytitle>
    <scientifictitle>A randomised controlled trial to evaluate the effects of D-Cycloserine in combination with exposure therapy, versus pill placebo and exposure therapy, in the treatment of pediatric Specific Phobia to improve symptoms of anxiety, fear and phobic avoidance.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pediatric Specific Phobia Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>D-Cycloserine and exposure therapy versus pill placebo and exposure therapy. Participants receive one individual intensive session (3 hours) of exposure therapy. The session involves assisting participants to systematically and gradually face their fears. Half the participants will receive D-Cycloserine (either 35mg or 70mg depending on child weight) at the commencement of the exposure therapy session. Each dose is given orally in a capsule. The exposure therapy is delivered via trained psychologists.</interventions>
    <comparator>Pill placebo (sugar pill) plus single session of exposure therapy (therapy is exactly the same as that provided in the D-Cycloserine condition)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anxiety Disorders Interview Schedule (ADIS) - Child/ Parent Versions</outcome>
      <timepoint>Pre-Treatment, Post-Treatment, 1 month Follow Up, 3 Month Follow Up and 12 Month Follow up.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Childrens Global Assessment Scale (CGAS) - This a global measure of level of functioning in children and adolscents.</outcome>
      <timepoint>Pre-Treatment, Post-Treatment, 1 month Follow Up, 3 Month Follow Up and 12 Month Follow up.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fear Survey Schedule for Children Revised</outcome>
      <timepoint>Pre-Treatment, Post-Treatment,1 month Follow Up, 3 Month Follow Up and 12 Month Follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Spence Children's Anxiety Scale</outcome>
      <timepoint>Pre-Treatment, Post-Treatment, 1 month Follow Up, 3 Month Follow Up and 12 Month Follow up.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Primary Diagnosis of any Anxiety Disorder
2. DSM-IV-TR Specific Phobia Diagnosis
3. If taking a selective-serotonin reuptake inhibitor (SSRI) medication, dose must be stable for one-month prior to study entry and remain unchanged.</inclusivecriteria>
    <inclusiveminage>7</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria for participants include:
1. Organic mental disorder
2. Other medications that are contraindicated with D-Cycloserine (DCS)
3. Pregnancy (this will be screened for and if sexually active be required to use birth control)
4. Psychosis
5. Pervasive developmental disorder
6. History of seizure
7. History of other serious medical condition that can be contraindicated with DCS (i.e. cardiovascular, liver, kidney, respiratory etc.)
8. Serious suicidal risk
9. Concurrent psychotherapy
10. Current diagnosis of tuberculosis (TB)
11. Currently taking medication that lowers seizure threshold (ie., clozapine)
12. Impaired intelligence (IQ; likely &lt; 70)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealment ensured by using numbered medication bottles of DCS and placebo for each client. Randomisation concealed with pharmacist/s responsible for dispensing pills in numbered containers.</concealment>
    <sequence>Permuted block randomisation generated by a computer-based random numbers table.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>5/03/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Allison Waters</primarysponsorname>
    <primarysponsoraddress>School of Applied Psychology
Griffith University
176 Messines Ridge Road
Mt Gravatt   Queensland   4122</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Griffith University</fundingname>
      <fundingaddress>School of Applied Psychology
Griffith University
176 Messines Ridge Road
Mt Gravatt   Queensland   4122</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Lara Farrell</sponsorname>
      <sponsoraddress>School of Applied Psychology
Gold Coast Campus
Griffith University
Parklands Drive
Southport Queensland 4222</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Thomas Ollendick</othercollaboratorname>
      <othercollaboratoraddress>Child Study Center 
460 Turner Street
Suite 207 
Blacksburg, Virginia, USA 24060</othercollaboratoraddress>
      <othercollaboratorcountry>United States of America</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Harry McConnell</othercollaboratorname>
      <othercollaboratoraddress>School of Medicine
Gold Coast Campus
Griffith University
Parklands Drive
Southport 
Queensland 4222</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Evelin Tiralongo</othercollaboratorname>
      <othercollaboratoraddress>School of Pharmacy
Gold Coast Campus
Griffith University
Parklands Drive
Southport Queensland 4222</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Caroline Donovan</othercollaboratorname>
      <othercollaboratoraddress>School of Applied Psychology
Griffith University
176 Messines Ridge Road
Mt Gravatt   Queensland   4122</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Melanie Zimmer-Gembeck</othercollaboratorname>
      <othercollaboratoraddress>School of Applied Psychology
Gold Coast Campus
Griffith University
Parklands Drive
Southport 
Queensland 4222</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this trial is to examine whether D-Cycloserine can augment a single session of graded exposure therapy in children and adolescents with a specific phobia. D-Cycloserine is an antibiotic drug traditionally used to treat tuberculosis. D-Cycloserine is a glutamatergic  partial N-methyl-D-aspartate (NDMA) agonist, which has recently been shown to facilitate fear extinction in humans and animals and has also demonstrated to improve treatment outcome when combined with exposure therapy in social phobia, acrophobia or fear of heights and OCD in adult samples. The drug has recently been successfully used to augment exposure therapy for children and adolescents with OCD.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Griffith University Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Griffith University
Gold Coast Campus
Parklands Drive
Southport 
Queensland 4222</ethicaddress>
      <ethicapprovaldate>28/02/2012</ethicapprovaldate>
      <hrec>PSY/03/09/HREC</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Lara Farrell</name>
      <address>School of Applied Psychology
Griffith Health Institute
Gold Coast Campus
GRIFFITH UNIVERSITY
QLD, 4222</address>
      <phone>+61755528224</phone>
      <fax>+61755528291</fax>
      <email>l.farrell@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Lara Farrell</name>
      <address>School of Applied Psychology
Griffith Health Institute
Gold Coast Campus
GRIFFITH UNIVERSITY
Parklands Drive
QLD, 4222</address>
      <phone>+61755528224</phone>
      <fax>+61755528291</fax>
      <email>l.farrell@griffith.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Lara Farrell</name>
      <address>School of Applied Psychology
Griffith Health Institute
Gold Coast Campus
GRIFFITH UNIVERSITY
QLD, 4222</address>
      <phone>+61755528224</phone>
      <fax>+61755528291</fax>
      <email>L.Farrell@griffith.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>